aTyr Pharma Announces Research Collaboration with Montefiore Einstein
aTyr Pharma announced a research collaboration with Albert Einstein College of Medicine / Montefiore Einstein to advance development and testing of ATYR2810, its anti-NRP2 monoclonal antibody, in pediatric osteosarcoma. The collaboration is led by Dr. Bang H. Hoang, whose research focuses on NRP2's role in bone and soft tissue cancers; ATYR2810 has shown anti-tumor effects in preclinical models across multiple tumor types and has completed GLP toxicology and cGMP manufacturing.
Key figures
- Relapse rate
- 40%
- Amputation rate
- approximately 10% of cases
- Us osteosarcoma new cases per year
- 1000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.